Vzarii Therapeutics Ltd

Vzarii Therapeutics Limited is a pre‑clinical stage biotechnology company dedicated to pioneering gene‑therapy approaches that tackle mitochondrial dysfunction – a key driver in many neurodegenerative disorders. Building on groundbreaking research conducted at Trinity College Dublin, the company’s mission is to discover and develop therapies that directly address the cellular energy deficits underlying conditions such as dry age‑related macular degeneration (dry AMD), glaucoma, Alzheimer’s disease, Parkinson’s disease and motor‑neuron disease.

At the heart of Vzarii’s pipeline is its lead asset, VZ‑103, an adeno‑associated virus (AAV)‑based gene therapy showing promising results for dry AMD. The platform technology is designed for adaptability, offering potential treatment pathways across a spectrum of neurodegenerative illnesses. By focusing on the mitochondria‑centred pathology, Vzarii aims to deliver disease‑modifying solutions to patients and clinicians seeking innovative, targeted interventions.